Milk Thistle (Silymarin)

📜 Historical Use

Milk thistle is a tall plant with large purple flowers, native to Europe and introduced into North America by early colonists. Its common names carry the tradition with them - milk thistle, Mary thistle, holy thistle - from Silybum marianum, synonym Carduus marianus. A 2018 review in Phytotherapy Research describes it as a therapeutic herb with a 2,000-year history of use and a member of the Asteraceae family, and notes that its clinical potential has been examined in alcoholic liver disease, non-alcoholic fatty liver disease, viral hepatitis, drug-induced liver injury and mushroom poisoning. NCCIH records the historical uses plainly: milk thistle was used for liver disorders and to increase breast milk production. Today it is promoted as a dietary supplement for liver disorders, diabetes, and other conditions. Set those two lists side by side and something uncomfortable emerges. The two uses the plant has carried for two millennia - the liver and the milk - are precisely the two where modern trials have come back conflicting, too limited, or negative, including two trials NCCIH funded itself and a randomised lactation trial that found no difference from placebo. The one place a positive signal has appeared, blood sugar control in type 2 diabetes, is not a traditional use at all and was studied largely in one region. On this page, tradition is not evidence about the liver. It is evidence of how long a use can persist without being confirmed.

📊 What the Research Shows

NCCIH opens its milk thistle assessment with a sentence that belongs on any page selling the herb: there is not enough high-quality evidence to allow definite conclusions to be reached about its effects on health conditions in people. On liver disease - the use milk thistle is famous for - results from clinical trials in alcohol-related liver disease, hepatitis B and C, non-alcoholic fatty liver disease, and liver problems caused by cancer chemotherapy, low oxygen levels or toxins have been conflicting or too limited to allow conclusions. Two trials funded by NCCIH itself, one in hepatitis C and one in non-alcoholic steatohepatitis, did not show benefits from silymarin. The NCCIH hepatitis C fact sheet is blunter: a 2014 evaluation of five studies involving 389 participants did not show silymarin to be beneficial, with no improvement in liver function and no decrease in hepatitis C virus levels, and a 2012 trial of 154 participants co-funded by NCCIH and NIDDK found that higher-than-usual doses given for 24 weeks were no better than placebo on liver function, virus levels, or quality of life. The one positive signal points elsewhere: a small number of studies suggest milk thistle extracts may help control blood sugar in type 2 diabetes, though most of that research was done in Middle Eastern countries and it is unclear whether the same results would be seen elsewhere. On increasing breast milk production NCCIH says the effect is unclear, and LactMed shows the shape of that uncertainty: a non-randomised study of 50 mothers in Peru reported large increases in milk volume, while a randomised trial in mothers of infants born before 32 weeks found no difference at any time point, and an evidence-based analysis of that trial graded it very low certainty evidence that micronized silymarin does not increase milk volume at day 28.

Take 200-400mg standardized silymarin (80%) 3x daily with meals for active liver issues. 200mg daily for prevention.

Generally very safe. May lower blood sugar. Mild laxative effect initially.

⚠️ What happens if taken in excess:

Very safe herb — remarkably low toxicity even at high doses. Doses above 1500mg/day may cause GI effects (diarrhea, bloating). Rare allergic reactions in people allergic to ragweed family. May lower blood sugar. Very rarely, headache and joint pain reported.

The useful thing to report here is how thin the federal record is, and which way it points. The only pharmacokinetic statement about drug handling in any source read for this page is one line in LactMed: milk thistle might increase the metabolism of some drugs. Increase, not decrease - which is the opposite of the claim most retail copy makes, that silymarin inhibits cytochrome P450 enzymes and therefore pushes drug levels up. No source read here names a cytochrome P450 isoform, a drug transporter, or a single interacting medicine for milk thistle, and a page that names one is going further than these sources do. NCCIH offers only its standing instruction: if you take any type of medicine, talk with your health care provider before using milk thistle or other herbal products, because some herbs and medicines interact in harmful ways. Two things sharpen that generic line. First, the product-quality problem described above is itself an interaction problem - if the silymarin content of a capsule can differ substantially from its label, whatever interaction exists is being run at an unknown dose. Second, the people most likely to take milk thistle are people with liver disease, whose drug metabolism is already altered and who are frequently on medicines with narrow margins. In the hepatitis C research NCCIH summarises, silymarin was given to patients previously treated with interferon and no interaction problem is reported, but those trials tested benefit, not interactions. Separately, the weak estrogen-receptor-beta activity reported in cell and rodent studies is a theoretical flag for anyone on hormonal therapy or with a hormone-sensitive condition; no source read here carries that finding into humans.

1. Milk Thistle: Usefulness and Safety — National Center for Complementary and Integrative Health NCCIH Herbs at a Glance (NIH) (2025)[NIH ↗]
2. Hepatitis C and Dietary Supplements — National Center for Complementary and Integrative Health NCCIH (NIH) (2018)[NIH ↗]
3. Milk Thistle — Drugs and Lactation Database (LactMed), National Institute of Child Health and Human Development NCBI Bookshelf NBK501771 (2026)[NIH ↗]
4. Milk thistle (Silybum marianum): a concise overview of its chemistry, pharmacological, and nutraceutical uses in liver diseases — Abenavoli L, Izzo AA, Milic N, et al. Phytotherapy Research (2018)[NIH ↗]
5. Botanicals and their bioactive phytochemicals for women's health — Dietz BM, Hajirahimkhan A, Dunlap TL, et al. Pharmacological Reviews (2016)[NIH ↗]